Medical treatment of benign prostatic hyperplasia
Abstract
Benign prostate hyperplasia (BPH) is a common disease, which affects male patients with incidence increasing with age. In recent years medical therapy for BPH has evolved, leading to postponement of surgical treatment. Alpha-blockers are considered first line treatment for patients with moderate to severe lower urinary tract symptoms (LUTS), while 5-alpha reductase inhibitors are prescribed in patients with moderate to severe LUTS and high risk of progression and acute urinary retention. Combination therapy is suitable for selected patients with LUTS and the choice of therapy depends on the main symptoms and risk of progression.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.